Law360 has published an in-depth profile of Lieff Cabraser partner Lin Y. Chan, named a Law360 Rising Star for 2017 for Competition. The profile highlights Ms. Chan’s biggest case to date (illegal non-compete agreements over the blockbuster antibiotic Cipro), where she gets her motivation, how she became a competition and antitrust attorney, and the advice she would give to young attorneys striving to be successful in the law.
Law360 notes that Chan “has notched several important victories for clients in competition cases, including some of the most significant settlements with chemicals and pharmaceutical companies in recent memory, placing her among the five competition law practitioners under age 40 honored by Law360 as Rising Stars.”
“Being able to challenge corporate fraud and cheating” drives her, Chan told Law360. “I think there’s a lot of corporate abuse out there that comes in many forms. That includes anti-competitive behavior that hurts consumers. As a consumer there’s very little you can do. It’s a lot of money that these corporations are essentially stealing from consumers. Absolutely that motivates me.”
About Lin Chan
A partner in Lieff Cabraser’s San Francisco office, Ms. Chan has represented plaintiffs in employment, whistleblower law, and antitrust cases. Her successes at the firm include Cipro, discussed above, as well as representing direct purchasers of titanium dioxide against the titanium dioxide manufacturers for conspiring to fix prices. She worked extensively on the case’s trial preparation, including drafting and arguing motions in limine. In 2013, the case settled before trial for $163 million.